[
    {
        "file_name": "HarpoonTherapeuticsInc_20200312_10-K_EX-10.18_12051356_EX-10.18_Development Agreement_Option Agreement.pdf",
        "perturbation": [
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "6.10\nInterest on Late Payments. If any payment due to either Party under this Agreement is not paid\nwhen due, then such paying Party shall pay interest thereon (before and after any judgment) at [***] such interest to run from the\ndate on which payment of such sum became due until payment thereof in full together with such interest; provided however that\n[***], then such interest [***], as adjusted from time to time on the [***].",
                "changed_text": "6.10\nInterest on Late Payments. If any payment due to either Party under this Agreement is not paid\nwhen due, then such paying Party shall pay interest thereon (before and after any judgment) at [***] such interest to run from the\ndate on which payment of such sum became due until payment thereof in full together with such interest; provided however that\n[***], then such interest [***], as adjusted from time to time on the [***]. Notwithstanding the foregoing, no interest shall accrue on any late payments, regardless of the reason for the delay.",
                "explanation": "This change introduces a direct contradiction within the same section regarding interest on late payments. The original text stipulates an interest rate, while the added sentence explicitly states that no interest will be charged, creating confusion and potential disputes.",
                "location": "Section 6.10"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "3.2.3\nLicense Option Exercise Notice. Upon the Effective Date, Harpoon hereby grants to\nAbbVie the exclusive right, but not the obligation, to obtain the licenses set forth in Section 5.1.3 (the “License Option”). AbbVie\nshall have the right to exercise its License Option by providing written notice of such election to Harpoon (“License Option\nExercise Notice”) at any time on or after the Effective Date and on or prior to the date that is [***] from AbbVie’s receipt of the\nOpt-In Development Report containing all items required pursuant to Section 1.112, as such period may be extended pursuant to\nSection 3.2.1 (the “License Option Period”). If AbbVie does not provide a License Option Exercise Notice within the License\nOption Period, then (a) Harpoon shall have no further obligations to perform any Initial Development Activities, (b) AbbVie’s License\nOption shall expire, and this Agreement shall terminate in accordance with Section 12.1.1, and (c) AbbVie shall have no further rights\nin connection with Licensed Compounds of the Licensed Products.",
                "changed_text": "3.2.3\nLicense Option Exercise Notice. Upon the Effective Date, Harpoon hereby grants to\nAbbVie the exclusive right, but not the obligation, to obtain the licenses set forth in Section 5.1.3 (the “License Option”). AbbVie\nshall have the right to exercise its License Option by providing written notice of such election to Harpoon (“License Option\nExercise Notice”) at any time on or after the Effective Date and on or prior to the date that is [***] from AbbVie’s receipt of the\nOpt-In Development Report containing all items required pursuant to Section 1.112, as such period may be extended pursuant to\nSection 3.2.1 (the “License Option Period”). If AbbVie does not provide a License Option Exercise Notice within the License\nOption Period, then (a) Harpoon shall have no further obligations to perform any Initial Development Activities, (b) AbbVie’s License\nOption shall be automatically extended for an additional six (6) months, and (c) AbbVie shall have no further rights in connection with Licensed Compounds of the Licensed Products, unless Abbvie extends it's option.",
                "explanation": "Here the changed_text modify a key term on whether the option expires or not. That key change has implications for the obligations, rights and financials of the parties. It is very important.",
                "location": "Section 3.2.3"
            },
            {
                "type": "Inconsistencies - In Text Contradiction",
                "original_text": "11.5\nSpecial, Indirect, and Other Losses. EXCEPT (A) FOR FRAUD, WILLFUL MISCONDUCT\nOR GROSS NEGLIGENCE, (B) FOR A PARTY’S BREACH OF ITS OBLIGATIONS UNDER [ARTICLE 9 OR SECTION 5.8],\n(C) AS PROVIDED UNDER [***] AND (D) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO\nA THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS\nARTICLE 11, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR INDIRECT, INCIDENTAL,\nSPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF PROFITS OR BUSINESS\nINTERRUPTION, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT,\nNEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE IN CONNECTION WITH OR ARISING IN ANY WAY\nOUT OF THE TERMS OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE USE OF\nTHE LICENSED COMPOUNDS OR LICENSED PRODUCTS, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH\nDAMAGES.",
                "changed_text": "11.5\nSpecial, Indirect, and Other Losses. EXCEPT (A) FOR FRAUD, WILLFUL MISCONDUCT\nOR GROSS NEGLIGENCE, (B) FOR A PARTY’S BREACH OF ITS OBLIGATIONS UNDER [ARTICLE 9 OR SECTION 5.8],\n(C) AS PROVIDED UNDER [***] AND (D) TO THE EXTENT ANY SUCH DAMAGES ARE REQUIRED TO BE PAID TO\nA THIRD PARTY AS PART OF A CLAIM FOR WHICH A PARTY PROVIDES INDEMNIFICATION UNDER THIS\nARTICLE 11, NEITHER PARTY NOR ANY OF ITS AFFILIATES SHALL BE LIABLE FOR INDIRECT, INCIDENTAL,\nSPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES, INCLUDING LOSS OF PROFITS OR BUSINESS\nINTERRUPTION, HOWEVER CAUSED AND ON ANY THEORY OF LIABILITY, WHETHER IN CONTRACT, TORT,\nNEGLIGENCE, BREACH OF STATUTORY DUTY OR OTHERWISE IN CONNECTION WITH OR ARISING IN ANY WAY\nOUT OF THE TERMS OF THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THE USE OF\nTHE LICENSED COMPOUNDS OR LICENSED PRODUCTS, EVEN IF ADVISED OF THE POSSIBILITY OF SUCH\nDAMAGES. Notwithstanding the forgoing, a Party may be liable for indirect, incidental, special, or consequential damages if a court of competent jurisdiction determines that such Party breached Section 4.2 of the agreement.",
                "explanation": "The original clause disclaims liability for consequential damages. However, the added sentence introduces an exception specifically for breaches of Section 4.2, creating uncertainty about the enforceability of the original disclaimer and opening the door to potential disputes over liability for such damages in specific cases.",
                "location": "Section 11.5"
            }
        ]
    }
]